$Centogene (CNTG.US)$ NEWS CENTOGENE and Evotec Discover Pro...
NEWS
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE and Evotec announced the discovery of a promising new molecule with potential to treat type 2 and type 3 Gaucher disease. The discovery stems from their ongoing drug discovery partnership initiated in 2020, now extended for another year. Evotec has received an R&D license for continued development and has an exclusive option until March 31, 2025, to license CENTOGENE’s share of the IP. If exercised, CENTOGENE will receive an upfront fee, milestone payments, and royalties. Preclinical studies show the molecule has high brain penetration and metabolic stability, indicating significant progress towards a treatment for neuronopathic Gaucher disease.
CENTOGENE and Evotec announced the discovery of a promising new molecule with potential to treat type 2 and type 3 Gaucher disease. The discovery stems from their ongoing drug discovery partnership initiated in 2020, now extended for another year. Evotec has received an R&D license for continued development and has an exclusive option until March 31, 2025, to license CENTOGENE’s share of the IP. If exercised, CENTOGENE will receive an upfront fee, milestone payments, and royalties. Preclinical studies show the molecule has high brain penetration and metabolic stability, indicating significant progress towards a treatment for neuronopathic Gaucher disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1084Followers
68Following
7486Visitors
Follow